The Federal Trade Commission filed a lawsuit in New York on 13 November 2026 seeking to stop veterinary supplier Covetrus from acquiring MWI Animal Health from Cencora in a transaction valued at $3.5 billion. The regulator argues that combining two leading distributors would remove an important source of price and service competition for American veterinary practices. The transaction remains proposed, and the allegations have not been adjudicated.
The dispute is about more than the price of a corporate acquisition. Veterinary clinics buy medicines, vaccines, surgical equipment and everyday supplies through distribution networks that promise rapid deliveries, large inventories and discounts. The FTC predicts fewer competing quotes would mean higher costs for clinics and ultimately pet owners. Those outcomes have not yet occurred and remain contested.
Key facts
- The FTC voted 2-0 to authorize a challenge and sought a permanent injunction in the US District Court for the Southern District of New York.
- The proposed $3.5 billion combination involves Covetrus and Cencora's MWI business; the companies announced their agreement in February 2026.
- Attorneys general from 13 states joined the complaint. A filed lawsuit is not a court finding that the acquisition is unlawful.
- Covetrus disputes the FTC's market description and says it intends to defend the deal.
Why veterinary supply competition matters
The complaint identifies two markets: distribution to veterinary clinics generally and distribution to large corporate veterinary accounts. The regulator says Covetrus and MWI directly compete for both independent practices and large groups operating hundreds of clinics. Their nationwide networks, inventory breadth and established discounts allegedly make it hard for smaller rivals to offer comparable service.
The FTC points to conduct that, it argues, demonstrates a competitive constraint. It alleges that Covetrus lowered prices and offered rebates through its VetSuite programme in response to aggressive MWI pricing. The Vetcove online price-comparison platform has also enabled veterinarians to compare bids and use one supplier's offer in negotiations with another. The regulator says removing a major alternative would undermine that bargaining mechanism.
The agency also argues that manufacturers, specialist distributors, retailers and sellers of agricultural animal products do not exert sufficient pressure on broad veterinary clinic distributors. That is a proposed market definition, however, and establishing it will be an important part of the litigation. Covetrus's response, reported by Reuters, says the complaint is based on an outdated and overly narrow view of purchasing behaviour.
The possibility of higher prices is therefore a legal and economic allegation, not an observed result of a consummated merger. The court may assess evidence about alternative suppliers, switching costs, discounts and fulfilment requirements. No buyer has been ordered to change purchasing practices as a result of the filing alone.
The February agreement and what happens next
Cencora and Covetrus announced the definitive agreement on 18 February 2026. Cencora said MWI had an enterprise value of $3.5 billion and that its consideration would include $1.25 billion in cash, $800 million in preferred equity and a retained, non-controlling common equity stake of 34.3% in the combined business. These are the transaction terms rather than direct consumer payments.
At that stage the businesses presented a combination of logistics, distribution and technology as a way to improve access to animal healthcare and reduce operating costs. Such projected efficiencies are the companies' commercial rationale. The FTC considers the loss of head-to-head competition more important, and its position has now been placed before a federal court.
The legal process will test the arguments and evidence offered by the plaintiffs and the defendants. The requested injunction would prevent the merger if granted, but filing for it does not itself determine the outcome. A negotiated resolution is another possibility, although none has been announced in the documents reviewed.
For clinics and pet owners, the immediate change is uncertainty about the future structure of veterinary supply distribution, rather than a new regulation on treatment or retail pricing. Purchasing costs and any effect on veterinary bills will depend on the market and the ultimate resolution of the case.
Sources: FTC announcement; Cencora transaction disclosure; Reuters reporting.



